Charles River Laboratories is to buy Wuxi PharmaTech for $1.6bn, as it anticipates sharply rising demand for outsourced early-stage research from large pharmaceuticals companies.
Charles River Laboratories将以16亿美元收购无锡药明康德(WuXi AppTec)，因其预期大型制药企业外包初期研究的需求将急剧上升。
您已阅读10%（258字），剩余90%（2252字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。